Abstract
Conotoxins are small bioactive highly structured peptides from the venom of marine cone snails (genus Conus). Over the past 50 million years these molluscs have developed a complex venom cocktail for each species that is comprised of 100-2000 distinct cysteine- rich peptides for prey capture and defence. This review focuses on an important and well-studied class of conotoxins, the α- conotoxins. These α-conotoxins are potent and selective antagonists of various subtypes of the nicotinic acetylcholine receptors (nAChRs). Key structure-activity relationship studies are presented to illustrate the common motifs, structural features and pharmacophores that define this interesting peptide class. Additionally, their synthesis, chemical modifications, the development of more selective and stable analogues and their therapeutic potential are discussed.
Keywords: -conotoxins, Conus, peptide synthesis, post-translational modifications, structure-activity relationships, nicotinic acetylcholine receptors (nAChRs), pharmacophores, cysteine residues, Radioactive iodine labeling, Point mutations
Current Pharmaceutical Design
Title: Structure-Activity Studies on Alpha-Conotoxins
Volume: 17 Issue: 38
Author(s): Markus Muttenthaler, Kalyana B. Akondi and Paul F. Alewood
Affiliation:
Keywords: -conotoxins, Conus, peptide synthesis, post-translational modifications, structure-activity relationships, nicotinic acetylcholine receptors (nAChRs), pharmacophores, cysteine residues, Radioactive iodine labeling, Point mutations
Abstract: Conotoxins are small bioactive highly structured peptides from the venom of marine cone snails (genus Conus). Over the past 50 million years these molluscs have developed a complex venom cocktail for each species that is comprised of 100-2000 distinct cysteine- rich peptides for prey capture and defence. This review focuses on an important and well-studied class of conotoxins, the α- conotoxins. These α-conotoxins are potent and selective antagonists of various subtypes of the nicotinic acetylcholine receptors (nAChRs). Key structure-activity relationship studies are presented to illustrate the common motifs, structural features and pharmacophores that define this interesting peptide class. Additionally, their synthesis, chemical modifications, the development of more selective and stable analogues and their therapeutic potential are discussed.
Export Options
About this article
Cite this article as:
Muttenthaler Markus, B. Akondi Kalyana and F. Alewood Paul, Structure-Activity Studies on Alpha-Conotoxins, Current Pharmaceutical Design 2011; 17 (38) . https://dx.doi.org/10.2174/138161211798999384
DOI https://dx.doi.org/10.2174/138161211798999384 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology α-Melanocyte Stimulating Hormone as a Potential Therapy for Alzheimer's Disease
Current Alzheimer Research Neurodegeneration and Neuroprotection in Multiple Sclerosis
Current Pharmaceutical Design Analysis of Electrical Brain Waves in Neurotoxicology: Gamma- Hydroxybutyrate
Current Neuropharmacology Inhibitors of AMPA and Kainate Receptors
Current Medicinal Chemistry Rab GTPases, Membrane Trafficking and Diseases
Current Drug Targets Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry The Role of Adenosine in Alzheimers Disease
Current Neuropharmacology Double-edged Role of K<sub>Na</sub> Channels in Brain Tuning: Identifying Epileptogenic Network Micro-Macro Disconnection
Current Neuropharmacology Pathophysiological Role of Mitochondrial Potassium Channels and their Modulation by Drugs
Current Medicinal Chemistry A Longitudinal FDG-PET Study of Transgenic Mice Overexpressing GSK- 3β in the Brain
Current Alzheimer Research Clinical Pharmacokinetics of Retigabine/Ezogabine
Current Clinical Pharmacology Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Interactions between Ketamine and Magnesium for the Treatment of Pain: Current State of the Art
CNS & Neurological Disorders - Drug Targets Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Gene Therapy for Angelman Syndrome: Contemporary Approaches and Future Endeavors
Current Gene Therapy Cellular Functions of Vaults and their Involvement in Multidrug Resistance
Current Drug Targets Viral M2 Ion Channel Protein: A Promising Target for Anti-influenza Drug Discovery
Mini-Reviews in Medicinal Chemistry Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Pharmacological Tools to Activate Microglia and their Possible use to Study Neural Network Patho-physiology
Current Neuropharmacology